Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. (Nasdaq: VIR) on September 1, 2020, reporting events that occurred on August 28, 2020. The filing addresses changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Kristina Burow resigned effective August 28, 2020, from her roles as a member of the Board of Directors and the Compensation Committee. The resignation was not the result of any disagreement with the Company.
- Appointment: Janet Napolitano was appointed to the Board as a Class I director, effective August 28, 2020, to fill the vacancy created by Ms. Burow's resignation. Her term extends until the 2023 annual meeting of stockholders.
- Committee Assignment: Ms. Napolitano was appointed to the Nominating and Corporate Governance Committee.
Compensation and Governance Details
Ms. Napolitano will receive compensation in accordance with the Company's non-employee director policy. On the effective date, she was granted an option to purchase 33,000 shares of common stock under the 2019 Equity Incentive Plan. Key terms include:
- Exercise Price: $41.64 per share (closing price on August 28, 2020).
- Vesting Schedule: One-third vests on the one-year anniversary of appointment; the remainder vests monthly over the subsequent two years, contingent on continued service.
- Term: 10 years.
- Indemnification: The Company entered into a standard indemnification agreement with Ms. Napolitano.
Key Facts for Investor Verification
- Confirm the effective date of Janet Napolitano's board appointment (August 28, 2020).
- Verify the vesting schedule and exercise price ($41.64) of the 33,000 share option grant.
- Note that the resignation of Kristina Burow was not due to any disagreement with the Company.
- Review the Company's 2020 Proxy Statement for full details on the non-employee director compensation policy referenced in this filing.